SCHEMBL212115

SCHEMBL212115

NC(=O)c1nccnc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.41
TSHR P16473 1/20 0.41
MC4R P32245 1/20 0.41
ADRA1A P35348 1/20 0.41
MC3R P41968 1/20 0.41
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KMT2A Q03164 2/20 0.39
TLR7 Q9NYK1 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
GLA P06280 1/20 0.35
IKBKB O14920 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
ASPH Q12797 1/20 0.33
KDM8 Q8N371 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29936207 1.00 ADORA3 (0.41) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL630383 0.83 KDM4E (0.44) TSHRHTTHSD17B10KMT2ATLR7
SCHEMBL30779709 0.83 KDM4E (0.44) TSHRHTTHSD17B10KMT2ATLR7
SCHEMBL4570471 0.81 HTT (0.38) TSHRHTTHSD17B10TLR7L3MBTL1
Hydrochloric Acid SCHEMBL629621 0.81 KDM4E (0.42) TSHRHTTHSD17B10KMT2ATLR7
SCHEMBL4570470 0.79 GLA (0.38) TSHRHTTHSD17B10KMT2ATLR7
SCHEMBL13990459 0.79 LMNA (0.42) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL30801476 0.79 HTT (0.37) TSHRHTTHSD17B10TLR7L3MBTL1
SCHEMBL629620 0.79 HTT (0.37) TSHRHTTHSD17B10TLR7L3MBTL1
SCHEMBL21147721 0.79 P2RX7 (0.42) ADORA3HTTHSD17B10TLR7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 EP claimed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 WO claimed
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS ACTIO BIOSCIENCES, INC. 2025-10-09 US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 EP disclosed
EP-3684184-B1 HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-06-21 EP disclosed
EP-3684184-B1 HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-06-21 EP disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 WO disclosed
CN-111372456-B Herbicidally active pyridyl-/pyrimidinyl-pyrazine derivatives 先正达参股股份有限公司 2022-10-18 CN disclosed
CN-113200985-B Pteridinone compound and preparation method and application thereof 南开大学 2022-09-09 CN disclosed
CN-101405258-B N-2-(hetero)arylethylcarboxamide derivative, and pest-controlling agent comprising the same NIHON NOHYAKU CO LTD 2013-07-24 CN disclosed
EP-2271632-B1 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS HOFFMANN LA ROCHE (CH) 2013-04-17 EP disclosed
US-8088920-B2 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US disclosed
US-8088920-B2 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US disclosed
CN-101981015-A 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents HOFFMANN LA ROCHE 2011-02-23 CN disclosed
CN-1956970-B Substituted pyrazinecarboxylic acid anilide derivative or salt thereof, intermediate thereof, agricultural/horticultural agent and use thereof NIHON NOHYAKU CO LTD 2010-12-08 CN disclosed
US-20090247550-A1 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-01 US disclosed
CN-101405258-A N-2-(hetero)arylethylcarboxamide derivative, and pest-controlling agent comprising the same NIHON NOHYAKU CO LTD (JP) 2009-04-08 CN disclosed
CN-1956970-A Substituted pyrazinecarboxylic acid anilide derivative or salt thereof, intermediate thereof, agricultural/horticultural agent and use thereof NIHON NOHYAKU CO LTD (JP) 2007-05-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247550-A1 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS CETP, APOB, PON1 ADORA3 419/4885TSHR 220/4885MC4R 627/4885
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS KCNT1, KCNT2, KCNN3 ADORA3 1717/4885TSHR 2956/4885MC4R 2549/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 ADORA3 1356/4885TSHR 1125/4885MC4R 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.